ESMO guidelines on renal cell carcinoma: the paradox of the fine line that separates scientific robustness from cost-efficiency analysis
- PMID: 34718116
- DOI: 10.1016/j.annonc.2021.10.212
ESMO guidelines on renal cell carcinoma: the paradox of the fine line that separates scientific robustness from cost-efficiency analysis
Conflict of interest statement
Disclosure EG reports speaker, consultancy or advisory roles for Advanced Accelerator Applications, Bristol Myers Squibb, Canada, Eisai, Japan, Eusa Pharma, IPSEN, France, Merck KGaA, Germany, MSD, Pfizer, United States and Roche, Switzerland; speaker's honoraria for Advanced Accelerator Applications, Astellas, Astra Zeneca, United Kingdom, Bristol Myers Squibb, Dr. Reddy's, Eisai, Eusa Pharma, IPSEN, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Pfizer, Roche and Sanofi-Genzyme; Steering committee member for Roche and GSK; Research grants from Astellas, AstraZeneca, IPSEN, Lexicon, Merck KGaA, MTEM/Threshold, United States/Tersera, Nanostring Technologies, Pfizer and Roche. BE reports speaker, consultancy or advisory roles for Pfizer, Bristol Myers Squibb, Eisai, IPSEN and Aveo.
Comment on
-
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.Ann Oncol. 2021 Dec;32(12):1511-1519. doi: 10.1016/j.annonc.2021.09.014. Epub 2021 Sep 28. Ann Oncol. 2021. PMID: 34597799 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical